Given that elevated levels of IL-6 are induced post-RFA treatment, surviving tumor cells at the periphery of the ablation zone may be inadvertently stimulated to proliferate by circulating IL-6, potentially leading to tumor recurrence and rapid progression. Here, IL6 is linked to neoplasm.